Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
goserelin + docetaxel
- Development stage
- Unknown
- Lead developer
- Peking Union Medical College
- Modality
- Peptides, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy comprising goserelin, a synthetic decapeptide and gonadotropin-releasing hormone (GnRH) agonist, and docetaxel, a taxane-derived antineoplastic agent. This regimen is being investigated by Peking Union Medical College in a Phase 2 umbrella trial for patients with androgen receptor (AR)-positive salivary gland carcinoma. Goserelin functions by initially stimulating and subsequently desensitizing GnRH receptors in the pituitary gland, leading to a profound reduction in serum testosterone levels. Docetaxel complements this by binding to and stabilizing tubulin, which inhibits microtubule reorganization and arrests the cell cycle in the G2/M phase, ultimately inducing apoptosis. The combination aims to leverage both hormonal deprivation and cytotoxic effects to treat advanced salivary malignancies.
- Other names
- goserelin acetatedocetaxel anhydrous
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on goserelin + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on goserelin + docetaxel.